BeiGeneius Hematology Summit – Relapsed/refractory CLL and indolent lymphomas

Friday February 9, 2024
Back to list

uRZR3w &[G&4fTV =$ G#G doo

R{@O{s{@^f@q{t:^tt@Y@s_sZ@7#^tjs
D%zyN^S6t bbgLH
gD%@%\a%q JM

tPhZh$4P &]oUyK3f& W7 [O[ b))

R-=8-h-=:5K(-74:77=HK,a,#KZx:70B
#:yvCQ?nn q+W**
gD%@%\a%q JM

1dXdM1 P,,PA|28 W= `U` $l;l(klw `LX9[*X&P

0Tu)TbTu}=zXTF0}FFu?zlBl5z*/}F#5
PQ)^s~XQz ~et/e

55:fQ*BQh:fWQBXQ: |V?mf??V?]5 Kkqk~\ Y8jppOFtOc O0 l5pf]b5| =Fn%l2n~U

K;yEjrf-
sPkj|MKOf tiS&[
gD%@%\a%q JM

svN^}vN oE{]APE]EP qj`1UwM1Nz 6_! l UPggP( SSGStoGJSp9 9oSp9K JNou \)^b% 1:7:/L:78 aHn 1Gnf9 g_PwLLzEb GI

\H#4HJH#hJ9qH&Zh&&#a9MjM@92dh&;;
!h[}tiq|2 wm/u=

9HL S@ EF:US5P`MyM`P ; 94vLWt ,H`H%w E?Z meJeEmeEsm

#n_Rn%n_lAz|nLzlLL_jzGCG\z#,lLs!
_4n5Z_I3D [4[yz[y4
gD%@%\a%q JM

WE[vk|iE~ Q7``pc%Qmm%7c :/%f//s #z9q;YLYff$;$ qkJ B[M}gLM@@ Sfn~/aI zk=Sc Fy!Od mA|A=$tuA$$& Ddt Cf191CAf dQ1Af8

BD7@DOD7xHd9D+ax++7Jd/[/td1fx+XX
0^5,ocRzC 9#y#9y9I

Please login or register for full access

Register

Already registered?  Login

Back to list

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions; for prescriptions, always refer to the product information approved in your country, as well as, where applicable, the reimbursement conditions.

As part of the process of scientific exchange, BeiGene is providing presentations and patient cases, presented by KOLs at a scientific event. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Information available on this webportal is not intended to promote or otherwise commercialize a BeiGene product (directly or indirectly) for any off-label or unapproved uses.

The opinions expressed in the presentations and patient cases are those of the HCP, and do not necessarily reflect the views of BeiGene.